NCT06986174View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

October 1, 2028

Study Completion Date

October 1, 2032

Conditions
Waldenström MacroglobulinemiaLymphoplasmacytic LymphomaB-Cell Lymphoproliferative DisorderIndolent Lymphoma
Interventions
DRUG

Pacritinib

Kinase inhibitor, capsule, taken orally per protocol.

Trial Locations (1)

02115

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Sobi, Inc.

INDUSTRY

lead

Shayna Sarosiek, MD

OTHER

NCT06986174 - A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia | Biotech Hunter | Biotech Hunter